Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taxotere and Doxil in Advanced Androgen-Independent Prostate Cancer
NCT00456989Phase 2Completed
- Sponsor
- University of Louisville
- Start
- Jan 2004
- Primary completion
- Aug 2010
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in prostate cancer (PCa), sponsored by University of Louisville. Primary endpoint: Maximum Tolerated Dose and Toxicity Profile at 2 years. Started Jan 2004; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00456989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00456989.